2005
DOI: 10.1177/0272989x05280559
|View full text |Cite
|
Sign up to set email alerts
|

Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model

Abstract: Epilepsy currently affects more than 400,000 people in the United Kingdom and 2.3 million in the United States. Drug therapy is the mainstay of treatment for patients with epilepsy, but therapies vary widely in their mechanism of action and acquisition cost. This article describes a decision model developed for the National Institute for Clinical Excellence in the United Kingdom. It compares the long-term cost-effectiveness of drugs licensed in adults for use in 3 situations: monotherapy for newly diagnosed pa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
25
0
1

Year Published

2005
2005
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 26 publications
(26 citation statements)
references
References 53 publications
0
25
0
1
Order By: Relevance
“…Für eine detaillierte Darstellung der verschiedenen Verfahren wird auf die Literatur verwiesen [31]. [18,39]. In einem "integrierten Modell" untersuchten die Autoren, basierend auf einer systematischen Datenauswertung, die Kosten pro QALY.…”
Section: Indirekte Kostenunclassified
“…Für eine detaillierte Darstellung der verschiedenen Verfahren wird auf die Literatur verwiesen [31]. [18,39]. In einem "integrierten Modell" untersuchten die Autoren, basierend auf einer systematischen Datenauswertung, die Kosten pro QALY.…”
Section: Indirekte Kostenunclassified
“…The majority of the clinical trials compared a single drug to placebo or one other alternative agent. However, as is usual in technology assessments for NICE [9], a direct comparison was not available for every possible pair-wise comparison. Thus, more advanced methods of evidence synthesis were necessary to combine direct and indirect information from multiple clinical trials.…”
Section: Meta-analysismentioning
confidence: 99%
“…Known as one of the most common neurological disorders worldwide, epilepsy has several treatment options. However pharmacotherapy remains the mainstay [3]. Since 1993 a high increase in emerging antiepileptic drugs (AEDs) has been observed [4].…”
Section: Introductionmentioning
confidence: 99%